Lisanti Capital Growth’s Ionis Pharmaceuticals IONS Stock Holding History

Lisanti Capital Growth’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.68M	Buy	75,699 +42,910	+131%	+$3.39M	1.43%	23
2025 Q4	$2.59M	Sell	32,789 -59,335	-64%	-$4.47M	0.61%	74
2025 Q3	$6.03M	Buy	+92,124	New	+$4.5M	1.47%	18
2024 Q3	–	Sell	-10,845	Closed	-$517K	–	133
2024 Q2	$517K	Sell	10,845 -16,990	-61%	-$697K	0.12%	114
2024 Q1	$1.21M	Sell	27,835 -34,580	-55%	-$1.65M	0.29%	102
2023 Q4	$3.16M	Buy	+62,415	New	+$2.99M	0.74%	62
2015 Q1	–	Sell	-36,805	Closed	-$2.27M	–	96
2014 Q4	$2.27M	Sell	36,805 -1,820	-5%	-$89.8K	1.14%	41
2014 Q3	$1.5M	Buy	+38,625	New	+$1.37M	0.75%	62
2014 Q1	–	Sell	-57,115	Closed	-$2.27M	–	113
2013 Q4	$2.27M	Buy	57,115 +39,390	+222%	+$1.4M	0.96%	52
2013 Q3	$665K	Buy	+17,725	New	+$529K	0.3%	95

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lisanti Capital Growth's IONS Position: Q1 2026 in Review

Lisanti Capital Growth increased its Ionis Pharmaceuticals (IONS) stake by 131% in Q1 2026, buying an estimated $3.39M and bringing the position to 75,699 shares worth $5.68M. The position accounts for 1.43% of the portfolio, ranked #23.

Lisanti Capital Growth first reported a position in IONS in Q3 2013 and has held it in 10 quarters since. The position peaked at $6.03M in Q3 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

Lisanti Capital Growth held 75,699 shares of Ionis Pharmaceuticals worth $5.68M as of Q1 2026.
Lisanti Capital Growth bought 42,910 Ionis Pharmaceuticals shares in Q1 2026, an estimated $3.39M.
Ionis Pharmaceuticals made up 1.43% of Lisanti Capital Growth's portfolio in Q1 2026, its #23 holding.
Lisanti Capital Growth first reported a position in Ionis Pharmaceuticals in Q3 2013 and has held it in 10 quarters since.
Lisanti Capital Growth's Ionis Pharmaceuticals position peaked at $6.03M in Q3 2025.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Lisanti Capital Growth's 13F filing for Q1 2026, filed 7 May 2026.